StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
40T.SI$0.32+0.00%
Fair $0.32+0.0%

40T.SI

ISEC Healthcare Ltd.

Healthcare / Medical Care FacilitiesSES

$0.32

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.32Fund rank 32/100 · Data gapFallback financials|
SA 49/C
F-Score: 4/9
Margin Compression

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $5.6M · quality 61.7/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 48/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

49/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Operating margin has declined for 3 consecutive years
Thesis & Journal · 40T.SILocal privado en este navegador · ISEC Healthcare Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$184M

P/E

16.0x

↓

EV/EBITDA

8.1x

↓

ROE

13.1%

↑

Gross Margin

42.1%

↓

Debt/Equity

0.27

↑
52-Week Range$0
$0$0

TradingView lightweight chart

40T.SI price, volumen y niveles de valoración

Último $0.320Periodo -13.5%
Fair value: $0.320

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+8.0%

FCF CAGR

—

FCF margin

-0.8%

FCF / Net income

-0.05x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $79.2M · net income $13.4M · FCF $-640000.0

2022-FY → 2025-FY

Gross margin

42.1%-3.6% pts

Operating margin

22.5%-6.1% pts

Net margin

16.9%-3.0% pts

FCF margin

-0.8%-20.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$79.2M$79.2M$74.2M$70.0M$63.0M
Net Income$13.4M$13.4M$12.8M$13.0M$12.5M
EBITDA$23.3M$23.3M$22.1M$21.9M$20.8M
EPS0.020.020.020.020.02
Gross Margin42.1%42.1%44.0%44.3%45.7%
Operating Margin22.5%22.5%24.6%26.2%28.6%
Net Margin16.9%16.9%17.3%18.5%19.9%
Balance Sheet
Debt/Equity0.270.270.150.160.17
Current Ratio2.382.38———
Cash Flow
Free Cash Flow$-640000.00$-640000.00$5.6M$13.7M$12.1M
Returns
ROE13.1%13.1%14.2%16.1%15.7%
Valuation
P/E16.0016.0017.9420.5814.19
EV/EBITDA8.068.0610.2811.898.21
P/B1.811.812.563.302.22
Growth & Yield
Revenue Growth6.8%6.8%6.0%11.2%—
EPS Growth4.0%4.0%-1.3%1.8%—
Dividend Yield1.8%1.8%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

7.0%

razonable

EPS terminal req.

$0.03

Spread vs growth

-2.9%

5Y implied EPS CAGR

8.2%

razonable

EPS terminal req.

$0.03

Spread vs growth

-4.1%

10Y implied EPS CAGR

9.1%

razonable

EPS terminal req.

$0.06

Spread vs growth

-5.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +0.3%

Total return

+0.3%

Start / end P/E

14.6x → 13.8x

EPS bridge

0.02 → 0.02

Residual

-0.2%

EPS growth+4.0%
Multiple rerating-5.4%
Dividend+1.8%
Residual / FX / buybacks / cross-term-0.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.